FDA Orphan Drug Designation Granted
The orphan drug designation will provide SFA Therapeutics with significant drug development and tax advantages as well as an expanded period of market exclusivity. Link to Press Release
Overview of SFA Therapeutics
SFA Therapeutics’ CEO Dr Ira Spector presents an overview of the company and its platform technology SFA Overview Presentation on YouTube Introduction to SFA Liver Disease and Oncology [...]
SFA Therapeutics on Money-Matters
Interview with SFA Therapeutics CEO on Money Matters TV- Charlie Huntington of Life Sciences Pa and Kimon Hatza, Esq. of MillCrest Law, LLP talk with Ira Spector, Ph. D. CEO of SFA Therapeutics [...]
